TY - JOUR
AU1 - Richman, Douglas D
AB - Antiviral Therapy 6: 83-88 Review Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor Douglas D Richman San Diego Veterans Affairs Healthcare System and University of California San Diego, Departments of Pathology and Medicine, La Jolla, Calif., USA For correspondence: Tel: +1 858 552 7439; Fax: +1 858 552 7445; E-mail: drichman@ucsd.edu Introduction Potent triple combination regimens have greatly in cell culture against feline and simian immuno- reduced the clinical progression, opportunistic infec- deficiency viruses (SIVs), animal lentiviruses related to tions and mortality associated with HIV infection HIV [4], and against HBV [5], for which it is being [1,2]. The success of combination regimens and the developed clinically. need for long-term adherence to treatment have led to Like other NRTIs, both emtricitabine and lamivu- the search for more potent, and less toxic antiretro- dine are activated to triphosphate (TP) derivatives, viral agents, more patient-friendly regimens and newer which mediate the antiviral effect. The TPs compete drug classes. Meanwhile, nucleoside reverse transcrip- with deoxycytosine TP (dCTP), the physiological tase inhibitors (NRTIs) continue to be an essential substrate, to inhibit HIV-1 reverse transcriptase (RT). component in almost all HIV regimens [3]. An optimal Both drugs lack a hydroxyl group at 
TI - Antiretroviral Activity of Emtricitabine, a Potent Nucleoside Reverse Transcriptase Inhibitor: 
JF - Antiviral Therapy
DO - 10.1177/135965350100600201
DA - 2000-02-01
UR - https://www.deepdyve.com/lp/sage/antiretroviral-activity-of-emtricitabine-a-potent-nucleoside-reverse-8WSst6o00j
SP - 83
EP - 88
VL - 6
IS - 2
DP - DeepDyve
ER -